All In Biotech

Drug Trial Radar · NCT06949020

A Dose-finding Study of JMKX003142 in Treatment of Cardiac Edema

Efficacy and Safety of JMKX003142 Injection in Heart Failure Patients With Volume Overload:A Phase II, Randomized, Double-blind, Placebo-controlled Study

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Jul 9, 2025

Primary completion

Mar 14, 2026

Study completion Apr 26, 2026

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
First posted
Apr 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To Evaluate the Safety, Efficacy, and Pharmacokinetic/Pharmacodynamics Characteristics of JMKX003142 injection Administered Randomly,Double-blind, Placebo-controlled Study in Chinese Cardiacl Edema Patients.

Conditions

  • Cardiac Edema

Interventions

  • JMKX003142 InjectionDrug

    JMKX003142 injection for experimental groups once daily for five days.

  • JMKX003142 InjectionDrug

    JMKX003142 injection for experimental groups once daily for five days.

  • JMKX003142 InjectionDrug

    JMKX003142 injection for experimental groups once daily for five days.

  • JMKX003142 placeboDrug

    JMKX003142 placebo for placebo groups once daily for five days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. body weightTime frame: 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital,School of Medicine,Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.